A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Inclusion Criteria:

1. Age ≥ 18 years
2. Willing and able to give written informed consent
3. Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021 criteria
4. Adequate organ function
5. Willing to comply with all protocol-required visits, assessments, and procedures
6. Able to swallow oral medication

Exclusion Criteria:

1. Prior treatment with an EGFR inhibitor for Glioblastoma
2. Currently enrolled in another therapeutic study
3. History of clinically significant cardiovascular disease
4. Gastrointestinal conditions that may affect administration/absorption of oral medications
5. Have an active infection (bacterial, fungal, or viral) requiring systemic therapy
6. Pregnant or breastfeeding women
7. Any serious underlying medical or psychiatric condition or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study
8. Known allergies, hypersensitivity, or intolerance to ERAS-801 or its excipients